BOXL vs LGND

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -19. 6% for Boxlight Corporation (BOXL). Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ligand Pharmaceuticals Incorporated (LGND) delivered a total return of +61.

0%, compared to -99. 0% for Boxlight Corporation (BOXL). Over 10 years, the gap is even starker: LGND returned +73. 0% versus BOXL's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ligand Pharmaceuticals Incorporated (LGND) is the lower-risk stock at 0.

99β versus Boxlight Corporation's 1. 25β — meaning BOXL is approximately 26% more volatile than LGND relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 33% for Boxlight Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -19. 6% for Boxlight Corporation (BOXL). On earnings-per-share growth, the picture is similar: Boxlight Corporation grew EPS 47. 4% year-over-year, compared to -107. 5% for Ligand Pharmaceuticals Incorporated. Over a 3-year CAGR, LGND leads at -11. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ligand Pharmaceuticals Incorporated (LGND) is the more profitable company, earning -2.

4% net margin versus -21. 8% for Boxlight Corporation — meaning it keeps -2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LGND leads at -13. 5% versus -15. 0% for BOXL. At the gross margin level — before operating expenses — LGND leads at 93. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

99)). Both have compounded well over 10 years (LGND: +73. 0%, BOXL: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BOXL (Technology) and LGND (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BOXL is a small-cap quality compounder stock; LGND is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.